NBI-1070770: Low Dose for Depression

"Indeed, the details on clinicaltrials.gov highlight the ongoing recruitment process for this trial. The study was initially posted on March 1st, 2024 and most recently updated on March 8th, 2024. A total of 72 participants are sought from two designated sites."

"The trial is seeking individuals over 18 years of age but under the age of 65 to enroll as participants."

"Our team at Power rated the safety of NBI-1070770: Medium Dose as 2 on a scale from 1 to 3. This rating is due to its Phase 2 trial status, indicating some evidence supporting safety but lacking data confirming efficacy."

"Affirmative. Evidence from clinicaltrials.gov indicates that this study is currently seeking participants. The trial was initially published on March 1, 2024, and last revised on March 8, 2024. Researchers aim to enroll a total of 72 patients distributed across two designated centers."

"This research is open to enrolling 72 individuals aged between 18 and 65 who are grappling with depression. Specifically, applicants must present a primary diagnosis of either recurrent MDD or persistent MDD. Of significant importance, candidates currently undergoing pharmacological therapy for their depressive symptoms should have maintained this treatment regimen for no less than eight weeks before the screening process and express readiness to persist with the current antidepressant medication protocol. Moreover, potential participants need to demonstrate willingness and capability in adhering to all outlined study protocols and limitations."